Thelma S. Angeles
UC San Diego Health System(US)Jacobs (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Cancer therapeutics and mechanisms, Lung Cancer Treatments and Mutations, Angiogenesis and VEGF in Cancer, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway(1998)292 cited
- → Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders(2007)251 cited
- → CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family(2001)204 cited
- Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).(1999)
- CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.(2003)
- → Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives(1997)119 cited
- → Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors(2016)113 cited